Related Experiment Video
Updated: May 31, 2026
06:47
Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique
Published on: September 20, 2011
Polymer--drug conjugates as nano-sized medicines
Fabiana Canal1, Joaquin Sanchis, María J Vicent
1Polymer Therapeutics Laboratory, Centro de Investigación Príncipe Felipe, Av. Autopista del Saler 16, E-46012 Valencia, Spain.
Current Opinion in Biotechnology
|July 5, 2011
Summary
Polymer therapeutics, including polymer-drug conjugates, are advancing. Key strategies involve new targets, combination therapies, improved polymer chemistry, and personalized medicine through biomarkers for broader clinical application.
Area of Science:
- Biotechnology
- Polymer Chemistry
- Drug Delivery
Background:
- Polymer therapeutics have significantly evolved since the 1990s.
- While some polymer-protein conjugates are established, polymer-drug conjugates are progressing through clinical trials.
- Further development is needed for polymer-drug conjugates to reach market approval.
Purpose of the Study:
- To outline key strategies for advancing polymer-drug conjugate technology.
- To identify areas for innovation in polymer therapeutics.
- To highlight the path toward clinical evaluation and personalized therapy.
Main Methods:
- Exploitation of novel molecular targets in cancer therapy.
- Development of combination therapy approaches.
- Advancement of polymer chemistry, including well-defined architectures and characterization techniques.
- Investigation of polymer conjugate features influencing clinical risk-benefit and identification of biomarkers.
Main Results:
- Four convergent strategies are proposed to advance polymer therapeutics.
- Focus on new disease targets and combination therapies offers new treatment avenues.
- Improvements in polymer design and characterization are crucial for clinical translation.
- Understanding clinical biomarkers enables personalized therapeutic strategies.
Conclusions:
- The advancement of polymer therapeutics requires a multi-faceted approach.
- Continued innovation in polymer chemistry and targeted therapies will drive progress.
- Personalized medicine, guided by biomarkers, represents a future direction for polymer conjugate therapy.
Related Concept Videos
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:23Factors Affecting Dissolution: Particle Size and Effective Surface Area
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are employed to...
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...